 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
ImmuCell Corporation (NASDAQ/ICCC), headquartered in Portland, Maine, is a biotechnology company dedicated to benefiting its employees and shareholders through the development, manufacture and sale of innovative and proprietary products that improve animal health and productivity in the dairy and beef industry. At ImmuCell Corporation, we have taken a number of important steps to solidify our governance practices, including adoption of a Code of Business Conduct and Ethics applicable to all of our employees. The Audit Committee of our Board of Directors oversees our accounting and financial reporting processes. Click here to view the Charter and Powers of the Audit Committee. Through documentation of these policies and practices, we have raised awareness of governance issues throughout our organization.
Get a FlashQuote or InfoQuote from NASDAQ AMEX. Download our latest Quarterly Report on Form 10-QSB. View our 2007 Annual Report on Form 10-KSB View our 2008 Proxy Statement To receive a paper copy of our current Annual Report, please visit www.prars.com or call 1-800-4-ANNUAL.
 June 5 2008 ImmuCell Initiates Pivotal Trial of Mast Out® May 5 2008 ImmuCell Announces Financial Results for First Quarter of 2008 March 12 2008 ImmuCell Announces Cross-License With Anadis July 19 2007 Immucell Announces Termination Of Mast Out® License And Return Of All Rights And Data From Pfizer June 7 2007 Governor Baldacci Attends Ceremony to Celebrate the Opening of ImmuCell's Renovated Facility in Conjuction with the Company's 2007 Annual Meeting of Shareholders
|
